Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats

Journal of Trauma and Acute Care Surgery

Volumn 74, Issue 2, 2013, Pages 499-507

  Bach IV, Harold H ^a   LaPorte, Heather M ^a   Wong, Yee M ^a   Gamelli, Richard L ^a   Majetschak, Matthias ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

26S proteasome; ATP; Bortezomib; Male Lewis rats; Resuscitation

Indexed keywords

ADENOSINE TRIPHOSPHATE; BORTEZOMIB; INTERLEUKIN 10; INTERLEUKIN 6; PEPTIDASE; PROTEASOME; PROTEASOME PEPTIDASE; TISSUE EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VOLUME; CONTROLLED STUDY; ENZYME ACTIVITY; FLUID RESUSCITATION; HEART MUSCLE; HEMORRHAGIC SHOCK; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PECTORAL MUSCLE; PILOT STUDY; PRIORITY JOURNAL; RAT; SURVIVAL TIME; VITAL SIGN;

ADENOSINE TRIPHOSPHATE; ANIMALS; BLOTTING, WESTERN; BORONIC ACIDS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; RATS; RATS, INBRED LEW; SHOCK, HEMORRHAGIC;

EID: 84875278673     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e31827d5db2     Document Type: Article

References (43)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425-479.
2. Orlowski M. The multicatalytic proteinase complex, a major extra-lysosomal proteolytic system. Biochemistry. 1990;29:10289-10297.
3. Baumeister W, Walz J, Zuhl F, et al. The proteasome: paradigm of a self-compartmentalizing protease. Cell. 1998;92:367-380.
4. Groll M, Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta. 2004; 1695:33-44.
5. Eytan E, Armon T, Heller H, et al. Ubiquitin C-terminal hydrolase activity associated with the 26 S protease complex. J Biol Chem. 1993;268: 4668-4674.
6. Orlowski M, Wilk S. Ubiquitin-independent proteolytic functions of the proteasome. Arch Biochem Biophys. 2003;415:1-5.
7. Tiao G, Hobler S, Wang JJ, et al. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest. 1997;99:163-168.
8. Hobler SC, Williams A, Fischer D, et al. Activity and expression of the 20S proteasome are increased in skeletal muscle during sepsis. Am J Physiol. 1999;277:R434-R440.
9. Mansoor O, Beaufrere B, Boirie Y, et al. Increased mRNA levels for components of the lysosomal, Ca2+-activated, and ATP-ubiquitinYdependent proteolytic pathways in skeletal muscle from head trauma patients. Proc Natl Acad Sci USA. 1996;93:2714-2718.
10. Bulteau AL, Lundberg KC, Humphries KM, et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem. 2001;276:30057-30063.
11. Keller JN, Huang FF, Zhu H, et al. Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury. J Cereb Blood Flow Metab. 2000;20:1467-1473.
12. Manning EW 3rd, Patel MB, Garcia-Covarrubias L, et al. Protea-some peptidase activities parallel histomorphological and functional consequences of ischemia-reperfusion injury in the lung. Exp Lung Res. 2009;35:284-295.
13. Majetschak M, Patel MB, Sorell LT, et al. Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. Biochem Biophys Res Commun. 2008;365:882-888.
14. Seiffert M, Gosenca D, Ponelies N, et al. Regulation of the ubiquitin proteasome system in mechanically injured human skeletal muscle. Physiol Res. 2007;56:227-233.
15. Patel MB, Earle SA, Majetschak M. Dynamics of tissue ubiquitin pools and ubiquitin-proteasome pathway component activities during the systemic response to traumatic shock. Physiol Res. 2007;56: 547-557.
16. Moore BS, Eustaquio AS, McGlinchey RP. Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol. 2008;12:434-440.
17. Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA. 1999;96:10403-10408.
18. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739-758.
19. Kukan M. Emerging roles of proteasomes in ischemia-reperfusion injury of organs. J Physiol Pharmacol. 2004;55:3-15.
20. Yao JH, Li YH, Wang ZZ, et al. Proteasome inhibitor lactacystin ablates liver injury induced by intestinal ischaemia-reperfusion. Clin Exp Pharmacol Physiol. 2007;34:1102-1108.
21. Tian XF, Zhang XS, Li YH, et al. Proteasome inhibition attenuates lung injury induced by intestinal ischemia reperfusion in rats. Life Sci. 2006;79:2069-2076.
22. Sinn DI, Lee ST, Chu K, et al. Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib. Neurosci Res. 2007;58:12-18.
23. Qu C, Mahmood A, Ning R, et al. The treatment of traumatic brain injury with velcade. J Neurotrauma. 2010;27:1625-1634.
24. Geng Q, Romero J, Saini V, et al. A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. Biochem Biophys Res Commun. 2009; 390:1136-1141.
25. Baker TA, Geng Q, Romero J, et al. Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation. Biochem Biophys Res Commun. 2010;401:548-553.
26. Jarrar D, Wang P, Chaudry IH. Metabolic disturbances in shock, and the role of ATP-MgCl2 and sex steroids. Med Princ Pract. 2004;13:2-9.
27. Kiang JG, Bowman PD, Lu X, et al. Geldanamycin prevents hemorrhage-induced ATP loss by overexpressing inducible HSP70 and activating pyru-vate dehydrogenase. Am J Physiol Gastrointest Liver Physiol. 2006;291: G117-G127.
28. Twombly R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst. 2003;95:845.
29. Hainz N, Thomas S, Neubert K, et al. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol. 2012;120:e47-e58.
30. Gribble FM, Loussouarn G, Tucker SJ, et al. A novel method for measurement of submembrane ATP concentration. J Biol Chem. 2000;275: 30046-30049.
31. Ando T, Imamura H, Suzuki R, et al. Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome RNA. PLoS Pathog. 2012;8:e1002561.
32. Beer M, Seyfarth T, Sandstede J, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267-1274.
33. Bottomley PA, Atalar E, Weiss RG. Human cardiac high-energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn Reson Med. 1996;35:664-670.
34. Kostler H, Landschutz W, Koeppe S, et al. Age and gender dependence of human cardiac phosphorus metabolites determined by SLOOP 31P MR spectroscopy. Magn Reson Med. 2006;56:907-911.
35. Kiang JG, Lu X, Tabaku LS, et al. Resuscitation with lactated Ringer solution limits the expression of molecular events associated with lung injury after hemorrhage. J Appl Physiol. 2005;98:550-556.
36. Blanchaer MC, Van Wijhe M. Isozymes of lactic dehydrogenase in skeletal muscle. Am J Physiol. 1962;202:827-829.
37. Jennische E, Amundson B, Haljamae H. Metabolic responses in feline "red" and "white" skeletal muscle to shock and ischemia. Acta Physiol Scand. 1979;106:39-45.
38. Chaudry IH, Sayeed MM, Baue AE. Alterations in high-energy phosphates in hemorrhagic shock as related to tissue and organ function. Surgery. 1976;79:666-668.
39. Costa D, Cancelliero KM, Polacow ML, et al. Metabolic profile of respiratory muscles of rats with bleomycin-induced pulmonary fi-brosis: relationship with oxidative stress. J Chin Clin Med. 2008;3: 123-132.
40. Huang H, Zhang X, Li S, et al. Physiological levels of ATP negatively regulate proteasome function. Cell Res. 2010:Dec;20(12):1372-1385.
41. Yu X, Huang S, Patterson E, et al. Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2005;289: H1960-H1967.
42. Huang S, Patterson E, Yu X, et al. Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyar-rhythmias and SCD in a model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2008;294:H1298-H1303.
43. Nowis D, Maczewski M, Mackiewicz U, et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol. 2010;176: 2658-2668.